JP2005522226A - 癌に関与するタンパク質 - Google Patents

癌に関与するタンパク質 Download PDF

Info

Publication number
JP2005522226A
JP2005522226A JP2003584724A JP2003584724A JP2005522226A JP 2005522226 A JP2005522226 A JP 2005522226A JP 2003584724 A JP2003584724 A JP 2003584724A JP 2003584724 A JP2003584724 A JP 2003584724A JP 2005522226 A JP2005522226 A JP 2005522226A
Authority
JP
Japan
Prior art keywords
polypeptide
cancer
raig1
expression
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003584724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005522226A5 (https=
Inventor
ジョナサン アレキサンダー テレット
Original Assignee
オックスフォード グライコサイエンシス （ユーケイ） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0208331.9A external-priority patent/GB0208331D0/en
Priority claimed from GB0221538A external-priority patent/GB0221538D0/en
Application filed by オックスフォード グライコサイエンシス （ユーケイ） リミテッド filed Critical オックスフォード グライコサイエンシス （ユーケイ） リミテッド
Publication of JP2005522226A publication Critical patent/JP2005522226A/ja
Publication of JP2005522226A5 publication Critical patent/JP2005522226A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2003584724A 2002-04-11 2003-04-10 癌に関与するタンパク質 Pending JP2005522226A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0208331.9A GB0208331D0 (en) 2002-04-11 2002-04-11 Proteins
GB0221538A GB0221538D0 (en) 2002-09-17 2002-09-17 A protein involved in carcinoma
PCT/GB2003/001587 WO2003087832A2 (en) 2002-04-11 2003-04-10 Diagnosis of carcinoma using raigi polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009284846A Division JP2010117358A (ja) 2002-04-11 2009-12-16 癌に関与するタンパク質

Publications (2)

Publication Number Publication Date
JP2005522226A true JP2005522226A (ja) 2005-07-28
JP2005522226A5 JP2005522226A5 (https=) 2006-07-06

Family

ID=29252443

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003584724A Pending JP2005522226A (ja) 2002-04-11 2003-04-10 癌に関与するタンパク質
JP2009284846A Abandoned JP2010117358A (ja) 2002-04-11 2009-12-16 癌に関与するタンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009284846A Abandoned JP2010117358A (ja) 2002-04-11 2009-12-16 癌に関与するタンパク質

Country Status (8)

Country Link
US (2) US20050282165A1 (https=)
EP (1) EP1497656B1 (https=)
JP (2) JP2005522226A (https=)
AT (1) ATE347106T1 (https=)
AU (1) AU2003222606A1 (https=)
DE (1) DE60310059T2 (https=)
ES (1) ES2274220T3 (https=)
WO (1) WO2003087832A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045224A1 (ja) * 2019-09-04 2021-03-11 国立大学法人東海国立大学機構 がん免疫療法等における免疫関連有害事象の予測

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1573034A4 (en) * 2002-06-20 2006-06-14 Bristol Myers Squibb Co IDENTIFICATION AND MODULATION OF A G-PROTEIN COUPLED RECEPTOR (GPCR) ASSOCIATED WITH COPD (CHRONIC-OBSTRUCTIVE LUNG DISEASE) AND NF-KB AND E-SELECTIN REGULATION, RAI3

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068618A1 (en) * 2000-07-26 2003-04-10 Muralidharu Padigaru Novel proteins and nucleic acids encoding same
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030068636A1 (en) * 2001-06-21 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6009018791, Ｅｎｄｏｃｒ． Ｒｅｌａｔ． Ｃａｎｃｅｒ ， ｖｏｌ． １２， ｐａｇｅｓ ６５−７３ （２００５） *
JPN6009018793, Ｇｅｎｏｍｉｃｓ， ｖｏｌ． ６５， ｐａｇｅｓ １２１−１２８ （２０００） *
JPN6009018794, Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．， ｖｏｌ． ２７３， ｐａｇｅｓ ３５００８−３５０１５ （１９９８） *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045224A1 (ja) * 2019-09-04 2021-03-11 国立大学法人東海国立大学機構 がん免疫療法等における免疫関連有害事象の予測
JPWO2021045224A1 (https=) * 2019-09-04 2021-03-11

Also Published As

Publication number Publication date
EP1497656A2 (en) 2005-01-19
DE60310059D1 (de) 2007-01-11
AU2003222606A1 (en) 2003-10-27
US20090258019A1 (en) 2009-10-15
US20050282165A1 (en) 2005-12-22
JP2010117358A (ja) 2010-05-27
WO2003087832A3 (en) 2004-02-12
ATE347106T1 (de) 2006-12-15
AU2003222606A8 (en) 2003-10-27
EP1497656B1 (en) 2006-11-29
ES2274220T3 (es) 2007-05-16
DE60310059T2 (de) 2007-05-10
WO2003087832A2 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
US8263071B2 (en) Protein involved in ovarian cancer
JP4532273B2 (ja) 癌に関係するタンパク質
US20110150877A1 (en) Ephrin-b receptor protein involved in carcinoma
US20070142276A1 (en) Protein involved in carcinoma
JP2010117358A (ja) 癌に関与するタンパク質
US20070141061A1 (en) Protein involved in carcinoma
US20070269431A1 (en) Protein Involved In Cancer
WO2005049066A2 (en) Use of dudulin2 for the treatment or prophylaxis of lung cancer
WO2006000753A2 (en) Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer
WO2006003427A1 (en) A protein involved in carcinoma
WO2005105143A2 (en) Vaccines and antibodies against ltk for therapy of cancers.
JP2008540624A (ja) 癌の処置／診断のためのｐｓｋ−１及びそのモジュレーター

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060407

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100409

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100415

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100514